Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir Pre-Emptive Therapy for CMV in HIV
NCT00006145Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2000
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of valganciclovir in cytomegalovirus infection (CMV), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2000; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00006145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006145.